Last reviewed · How we verify
Bryostatin for Injection
Bryostatin for Injection is a Cytotoxic agent Small molecule drug developed by Blanchette Rockefeller Neurosciences Insitute. It is currently in Phase 2 development for T-cell lymphoma. Also known as: Bryostatin 1, Bryostatin, NSC 339555, CAS No. 83314-01-6.
Activates protein kinase C (PKC)
Activates protein kinase C (PKC) Used for T-cell lymphoma.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Bryostatin for Injection |
|---|---|
| Also known as | Bryostatin 1, Bryostatin, NSC 339555, CAS No. 83314-01-6 |
| Sponsor | Blanchette Rockefeller Neurosciences Insitute |
| Drug class | Cytotoxic agent |
| Target | Protein kinase C (PKC) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bryostatin is a natural product that activates protein kinase C (PKC), a family of enzymes involved in cell signaling pathways.
Approved indications
- T-cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bryostatin for Injection CI brief — competitive landscape report
- Bryostatin for Injection updates RSS · CI watch RSS
- Blanchette Rockefeller Neurosciences Insitute portfolio CI
Frequently asked questions about Bryostatin for Injection
What is Bryostatin for Injection?
How does Bryostatin for Injection work?
What is Bryostatin for Injection used for?
Who makes Bryostatin for Injection?
Is Bryostatin for Injection also known as anything else?
What drug class is Bryostatin for Injection in?
What development phase is Bryostatin for Injection in?
What are the side effects of Bryostatin for Injection?
What does Bryostatin for Injection target?
Related
- Drug class: All Cytotoxic agent drugs
- Target: All drugs targeting Protein kinase C (PKC)
- Manufacturer: Blanchette Rockefeller Neurosciences Insitute — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for T-cell lymphoma
- Also known as: Bryostatin 1, Bryostatin, NSC 339555, CAS No. 83314-01-6
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing